LDS/Medical Tests/Ashkenazi Jewish Panel

Ashkenazi Jewish Panel

The Ashkenazi Jewish Panel detects autosomal recessive mutations that commonly occur in Ashkenazi Jewish (Eastern European Jewish) individuals. The most common disorders include Bloom syndrome, Canavan disease, Familial dysautonomia, Fanconi anemia group C, Gaucher disease, Niemann-Pick disease types A and B, and Tay-Sachs disease. The American College of Medical Genetics (ACMG) recommends routine preconceptual or prenatal carrier screening for these 8 different diseases common to individuals of Ashkenazi Jewish descent. The panel is used to screen Ashkenazi Jewish individuals for gene mutation carrier status, which would help in assessing risk of having a child with any of 8 genetic disorders commonly occurring in the Ashkenazi Jewish population. Since all of these disorders are autosomal recessive, both parents must be carriers for the couple to have an affected child. If one partner is Ashkenazi Jewish and the other is not, sequential screening, beginning with the Ashkenazi Jew, is recommended. About 1 in 25 people of Ashkenazi Jewish descent are also carriers of the Cystic Fibrosis gene; therefore, the American College of Medical Genetics suggests screening for this gene in this group who are pregnant or might become pregnant.

Bloom syndrome (BLM): Bloom syndrome is a rare, autosomal recessive genetic trait identified in the Ashkenazi Jewish (1 in 40,000) population. This genetic disorder is characterized by unusually small stature with normal body proportions with exception of a proportionally smaller cranium. Individuals with BLM have increased sensitivity to light and have multiple small, dilated blood vessels on the face. They experience an increased susceptibility to infections, especially in the upper respiratory tract, the middle ear, and lungs. Individuals with BLM have an increased susceptibility to cancer, especially to leukemia and lymphoma. Women with BLM are fertile but experience earlier menopause while BLM men are infertile.

Canavan disease (ASPA gene mutation): A neurologic disease characterized by decreased muscle tone, increased head circumference, and decreased motor activity and developmental delays by the age of three to five months. Canavan disease symptomatic individuals have very high concentration of N-acetyl aspartic acid (NAA) in the urine. The ASPA gene encodes for the enzyme aspartoacylase and is the gene associated with Canavan disease.

Cystic fibrosis (CF): Cystic fibrosis affects the epithelia of the respiratory tract, pancreas, male genital tract, exocrine sweat glands, and hepatobiliary system. Individuals with CF have recurrent lung infections that progress to lung disease. More than 95% of males are infertile as a result of azoospermia.

Familial Dysautonomia (FD): Familial Dysautonomia affects the development of sensory and autonomic nervous system function, which includes abnormal regulation of body temperature, gastrointestinal abnormalities, and decreased sensitivity to pain. It is caused by mutations of the IKBKAP gene. Neuron degeneration progresses throughout life, and life expectancy is decreased.

Fanconi anemia group C (FANCC): Characterized by aplastic anemia with abnormal bone development and bone marrow function, often leading to myelodysplastic syndrome or acute myelogenous leukemia. Affected individuals have one or more of the following: abnormal skin pigmentation, short stature, malformations of limbs, skeletal system, kidneys and urinary tract, heart, central nervous system, gastrointestinal system, and developmental delay.

Gaucher disease: Gaucher disease (GD) is an autosomal inherited lysosomal storage disease in which a metabolic deficiency of the enzyme beta-glucocerebrosidase occurs resulting in the accumulation of lipids throughout the body, especially in the bone marrow, liver and spleen. IT is caused by mutations of the GBA gene and there are three clinical types: Type 1, Type 2 and Type 3. Type 1 accounts for about 95% of cases in all populations. Although the manifestations of disease vary, the most common symptoms of Gaucher disease are an abnormally enlarged liver and/or spleen (hepatosplenomegaly), anemia, thrombocytopenia, and skeletal abnormalities.

Niemann-Pick disease types A and B (SMPD1 gene mutation): Characterized is a lysozomal storage disease. It is defined by diminished acid sphingomyelinase enzyme activity. Type A individuals have an enlarged liver and spleen, and mental degeneration. Type B individuals have an enlarged liver and spleen but no neurologic degeneration.

Tay-Sachs disease (HEXA gene mutation): Tay-Sachs disease is characterized by developmental retardation followed by seizures, dementia, and loss of motor skills, increased startle response, and blindness with death by 4 years of age. A later onset with slower progression is associated with adult onset. Tay-Sachs disease is caused by hexosaminidase A enzyme deficiency due to gene mutation.

  • Aid in diagnosis of Ashkenazi Jewish diseases
  • Determine carrier status in Ashkenazi Jewish individuals
  • Prenatal at risk assessment
  • Carrier screening for family planning

In Bloom syndrome the product of the altered gene is an altered helicase protein.

In Canavan disease, mutation of the ASPA has the result of a type of brain degeneration characterized as spongy. ASPA mutations are typically sought, including Y231X, E285A, 433(-2)A->G and A305E.

In Cystic Fibrosis only homozygous and compound heterozygous (two or more heterozygous mutations together) usually manifest in affected phenotype.

Familial Dysautonomia patients have mutations in the IKBKAP gene. In the Ashkenazi population there are two primary mutations: R696P and IVS20(+6)T->C.

For sufferers of Fanconi Anemia, mutations in multiple genes have been implicated; however, the most commonly involved gene in the Ashkenazi population is IVS4(+4)A->T mutation of the FANCC gene.

Patients with Gaucher's Disease have a mutation in the beta-glucocerebrosidase gene. There are three main types, and type 1 is the most common, being identified in about 95% of patients. In this type there is a large range of phenotypic expression, from relatively mild to severe.

Patients with Niemann-Pick disease have mutations in the SMPD1 gene, and these cause both types A and B. In the Ashkenazi group, the most common mutations in type A are fsP330, L302P and R496L.

Tay-Sachs patients develop an accumulation of the sphingolipid GM2 ganglioside due to deficiency of hexosaminidase enzyme, which is caused by mutations in the HEXA gene. The three most common mutations in the Ashkenazi population are G269S, 1278insTATC and IVS12+1G–C.

For more see table below.

Disease Mutations [Carrier Rate]: Tested

BLM [1%]:

  • 2281del6/ins7FD [3.1%]:
  • c.2087G>C
  • c.2204 +6T>C (formerly IVS20(+6)T>C)ASPA [2%]:
  • Y231X(C>A)
  • A305E
  • 433(-2)A>G
  • E285A
  • Polymorphism: Y231Y(C>T)FANCC [1.1%]:
  • 322delG
  • IVS4(+4)A>TGBA [6.6%]:
  • N370S
  • 84G>GG
  • IVS(+1)G>A
  • del55bp
  • V394L
  • D409H
  • R496H
  • L444PHEXA [3.3%]:
  • IVS12(+1)G>C
  • 1278insTATC
  • IVS9(+1)G>A
  • del7.6kb
  • G269SSMPD1 [1.1%]:
  • R496L
  • 1bp del fsP330
  • L302P
  • R608del

CF testing has 32 or more mutations for carrier status (for more see cystic fibrosis testing)

Negatives for mutation analyzed

Multiplex-polymerase chain reaction (PCR) amplification, allele specific primer extension (ARMS), Invader technology, Next generation sequencing, Sanger sequencing, PCR based chip array using ARMS, Oligonucleotide ligation assay, Mutation analysis.

Whole Blood EDTA (Lavender)

Stability

  • Ambient:  8 days
  • Refrigerated: 8 days
  • Frozen: Unacceptable
Further mutation testing for individual test, Usher Syndrome Type IF, Usher Syndrome Type III, Nemaline Myopathy, Maple syrup urine disease, Glycogen storage disease, Familial Hyperinsulinism (FHI), Dihydrolipoamide Dehydrogenase Deficiency (DLD) **Canavan disease**: N-acetylasparatic acid (NAA), Aspartoacylase enzyme activity **Gaucher disease**: β-glucosylceramidase enzyme activity, Bone marrow examination **Tay-Sachs disease**: HEX A enzymatic activity **Fanconi Anemia Group C**: Cytogenetic analysis (Chromosomal breakage studies) **Cystic Fibrosis**: Sweat chloride test, Semen analysis, Trans epithelial nasal potential difference (NPD) **Bloom syndrome**: Cytogenetic analysis (specifically sister-chromatid exchanges (SCE) analysis).
Approximately 2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login